Locations:
Search IconSearch

Tag: ruxolitinib

Dr. Gerds with a patient
April 7, 2025/Cancer/Blood Cancers

Positive Results from Phase 3 Trial of Pelabresib + Ruxolitinib for JAK Inhibitor-Naive Myelofibrosis

Combination therapy doubles the number of meaningful spleen volume responses over monotherapy

Myelofibrosis cells
March 18, 2025/Cancer/Blood Cancers

Personalizing Treatment of Myelofibrosis-Associated Anemia

Combination therapy may help address underlying disease

BackPage 1 of 1Next

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Ad